This first-in-human (FIH) study will provide the first safety and pharmacokinetic (PK) data for G1T38 in humans and will allow further development of G1T38 in patients with cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
76
CDK 4/6 Inhibitor
Placebo
PRA Early Development Clinic
Groningen, Netherlands
Number of Treatment Related Adverse Event, including Abnormal Laboratory Events
All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all subjects receiving study drug through 7 days post dose of study drug.
Time frame: Up to Day 7
Pharmacokinetics of G1T38: Maximum Plasma Concentration (Cmax)
The observed peak plasma concentration determined from the plasma
Time frame: Day 1, 2, 3, 4 and 5
Pharmacokinetics of G1T38: Area under Curve - plasma concentration (AUC)
Area under the plasma concentration-time curve
Time frame: Day 1, 2, 3, 4 and 5
Pharmacokinetics of G1T38: Plasma: terminal half life (T1/2)
G1T38: Plasma- terminal half life (T1/2)
Time frame: Day 1, 2, 3, 4 and 5
Pharmacokinetics of G1T38: Plasma - Volume of distribution
Volume of distribution in the terminal elimination phase
Time frame: Day 1, 2, 3, 4 and 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.